Do we know the best therapy for early endometrial cancer?

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

The HRAS1 minisatellite locus and risk of ovarian cancer.

Cancer research·2000

Masculinizing granulosa cell tumor of the ovary in a postmenopausal woman. A case report.

The Journal of reproductive medicine·1999

Endometrial cancer: current concepts and management.

Surgical oncology clinics of North America·1998

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

Gynecologic oncology·1996

Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma.

International journal of radiation oncology, biology, physics·1995

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Gynecologic oncology·2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Gynecologic oncology·2026

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Gynecologic oncology·2026

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Gynecologic oncology·2026

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Gynecologic oncology·2026

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Gynecologic oncology·2026

Assessment of Natural Killer Cell Serial Degranulation.

Current protocols·2026

Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway.

Cancer research·2026

Stimuli-responsive nanocarriers for precision cation channel therapy.

Chemical communications (Cambridge, England)·2026

Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

ATF7 drives diabetic wound healing via NOTCH1 repression and N1ICD-dependent macrophage polarization control.

JCI insight·2026

Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes.

JCI insight·2026

Related Experiment Videos

Do we know the best therapy for early endometrial cancer?

Related Concept Videos

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

The HRAS1 minisatellite locus and risk of ovarian cancer.

Masculinizing granulosa cell tumor of the ovary in a postmenopausal woman. A case report.

Endometrial cancer: current concepts and management.

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Assessment of Natural Killer Cell Serial Degranulation.

Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway.

Stimuli-responsive nanocarriers for precision cation channel therapy.

Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations.

ATF7 drives diabetic wound healing via NOTCH1 repression and N1ICD-dependent macrophage polarization control.

Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes.

Related Experiment Videos

Do we know the best therapy for early endometrial cancer?

Related Concept Videos

Related Articles